Niowave holds 12.18% of Aptevo (NASDAQ: APVO) — 151,723 shares

Rhea-AI Filing Summary

Niowave, Inc. reported beneficial ownership of 151,723 shares of Aptevo Therapeutics Inc. common stock, representing 12.18% of the class based on 1,246,105 shares outstanding as of May 13, 2026. The filing is a Schedule 13G signed June 22, 2026, and states the position was not acquired to change or influence control.

Insights

Institutional Ownership Analyst

Niowave holds a >10% passive stake in Aptevo.

Niowave reports 151,723 shares or 12.18% of Aptevo common stock, calculated from 1,246,105 outstanding shares as of May 13, 2026. The Schedule 13G disclosure indicates a passive reporting status rather than an active control intent.

The filing explicitly states the shares "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control"; subsequent filings would show any change in intent or activity.

Corporate Governance Specialist

Crossing the 10% threshold triggers public disclosure obligations.

Holding above 10.00% requires disclosure under beneficial ownership rules; the Schedule 13G format signals a passive investor position. The filing lists sole voting and dispositive power over 151,723 shares.

Monitor future filings for any amendment to a Schedule 13D or Form 4s that would indicate active engagement, as this Schedule 13G asserts no control intent.

Key Figures

Shares beneficially owned: 151,723 shares Percent of class: 12.18% Outstanding shares (basis): 1,246,105 shares +1 more

4 metrics

Shares beneficially owned 151,723 shares reported in Schedule 13G

Percent of class 12.18% calculated from 1,246,105 shares outstanding

Outstanding shares (basis) 1,246,105 shares as of May 13, 2026 (Form 10-Q referenced)

Filing signature date 06/22/2026 Schedule 13G signed by Controller

Key Terms

Schedule 13G, beneficially owned, sole dispositive power

3 terms

Schedule 13G regulatory

"The filing is a Schedule 13G signed June 22, 2026"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

beneficially owned regulatory

"Amount beneficially owned: 151,723 (b) Percent of class: 12.18 %"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole dispositive power regulatory

"Sole power to dispose or to direct the disposition of: 151,723"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 06/22/2026 - 12:11 PM Accepted by SEC EDGAR 06/22/2026 - 12:11 PM Learn about SEC filing dates

FAQ

What stake did Niowave report in Aptevo (APVO)?

Niowave reported beneficial ownership of 151,723 shares, equal to 12.18% of Aptevo common stock. The percentage is calculated from 1,246,105 shares outstanding as of May 13, 2026, per the filing.

Does Niowave claim control of Aptevo after this filing?

No. The Schedule 13G states the securities "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control" of Aptevo. The filing thus reports a passive position rather than a control intent.

When was the Schedule 13G for APVO signed?

The filing was signed by Jaime A Lerma, Controller, on June 22, 2026. The ownership percentage references shares outstanding from a Form 10-Q dated May 13, 2026 as the basis for calculation.

What voting and dispositive powers did Niowave report for APVO shares?

Niowave reported sole voting power and sole dispositive power over 151,723 shares, and 0 shared voting or dispositive power, as disclosed in the Schedule 13G filing.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Aptevo Therapeutics Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

03835L702

(CUSIP Number)

05/25/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 03835L702

1

Names of Reporting Persons

NIOWAVE, INC.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MICHIGAN

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 151,723.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 151,723.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

151,723.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

12.2 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: The calculation of percentage owned is based on 1,246,105 outstanding shares referenced in the Form 10-Q filed with the SEC on May 13, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Aptevo Therapeutics Inc.
(b)	Address of issuer's principal executive offices: 2401 4TH AVE., SUITE 1050, SEATTLE, WASHINGTON, 98121
Item 2.
(a)	Name of person filing: Niowave, Inc.
(b)	Address or principal business office or, if none, residence: 1012 N Walnut St, Lansing, MI 48906
(c)	Citizenship: United States
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 03835L702
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 151,723
(b)	Percent of class: 12.18 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 151,723
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 151,723
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

NIOWAVE, INC.

Signature:	Jaime A Lerma
Name/Title:	Controller
Date:	06/22/2026